Photo by nci from unsplash
The MYBPC3 (Myosin-binding protein C) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland, allowing unique opportunity to explore the relation between genotype and clinical phenotype.… Click to show full abstract
The MYBPC3 (Myosin-binding protein C) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland, allowing unique opportunity to explore the relation between genotype and clinical phenotype. This study explores the burden of diastolic dysfunction in a
Keywords:
myosin binding;
hypertrophic cardiomyopathy;
binding protein;
founder mutation
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!